Foghorn Therapeutics Extends Cash Runway to 2028 with $50M Financing
Event summary
- Foghorn Therapeutics completed a $50M registered direct financing in January 2026, extending cash runway into the first half of 2028.
- FHD-909 (LY4050784) Phase 1 dose-escalation trial is advancing as planned, targeting SMARCA4-mutant cancers with a focus on NSCLC.
- Selective CBP and EP300 degrader programs are on track for IND-enabling studies in 2026.
- Foghorn appointed Ryan Maynard as Chief Financial Officer in February 2026.
The big picture
Foghorn Therapeutics' recent financing and strategic advancements come at a time when the biotech industry is increasingly focused on targeted therapies for genetically defined cancers. The company's Gene Traffic Control® Platform positions it to capitalize on the growing demand for precision oncology treatments. With a strong balance sheet and a pipeline of first-in-class candidates, Foghorn is well-positioned to compete in the crowded oncology space, but must demonstrate clinical efficacy to attract further investment and partnerships.
What we're watching
- Clinical Progress
- Whether FHD-909 Phase 1 trial results will support combination studies in front-line NSCLC.
- Financial Strategy
- How Foghorn will allocate the $50M financing to advance its pipeline and extend cash runway.
- Competitive Positioning
- The pace at which Foghorn can differentiate its degrader programs in the competitive oncology landscape.
Related topics